KESTRA MEDICAL TECHNOLOGIES, LTD.
For the period ended Jul 31, 2025. Filed Sep 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jul 31, 2025 · Filed Sep 12, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months Ended July 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue | $19,371 | $12,782 |
| Cost of revenue | 10,520 | 8,582 |
| Gross profit | 8,851 | 4,200 |
| Operating expenses: | ||
| Research and development | 4,001 | 3,404 |
| Selling, general and administrative | 33,728 | 19,227 |
| Total operating expenses | 37,729 | 22,631 |
| Loss from operations | (28,878) | (18,431) |
| Other expense (income): | ||
| Interest expense | 1,912 | 1,874 |
| Interest income | (2,167) | (37) |
| Other expense (income) | (2,830) | 48 |
| Net loss before provision for income taxes | (25,793) | (20,316) |
| Provision for income taxes | 33 | 7 |
| Net loss and comprehensive loss | (25,826) | (20,323) |
| Net loss attributable to non-controlling interest | — | (439) |
| Net loss and comprehensive loss attributable to Kestra Medical Technologies, Ltd. | (25,826) | (19,884) |
| Less: Undeclared preferred stock dividends | — | 2,383 |
| Net loss attributable to common shareholders, basic and diluted | $(25,826) | $(22,267) |
| Net loss per share attributable to common shareholders, basic and diluted | $(0.50) | $(1.12) |
| Weighted-average shares of common shares outstanding, basic and diluted1 | 51,304,599 | 19,885,382 |
1 Weighted-average shares of common stock outstanding, basic and diluted, has been adjusted on a retrospective basis. Refer to Note 16 “Net Loss Per Share Attributable to Common Shareholders” for additional disclosure.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE PREFERRED STOCK AND
SHAREHOLDERS’ EQUITY (DEFICIT)
| Redeemable Preferred Stock · Common Shares · AdditionalPaid-In · Accumulated · Non-controlling · TotalShareholders’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Deficit | Interests | Equity (Deficit) | |
| Balances at April 30, 20242 | 177,110 | $177,110 | 19,909,281 | $19,909 | $177,149 | $(406,435) | $— | $(209,377) |
| Share-based compensation expense | — | — | — | — | 377 | — | — | 377 |
| Issuance of redeemable preferred stock | 103,400 | 103,400 | — | — | — | — | — | — |
| Issuance of stock to non-controlling interest | — | — | — | — | — | — | 17,100 | 17,100 |
| Deemed dividend for payments to third party on behalf of shareholder | — | — | — | — | (4,248) | — | — | (4,248) |
| Net loss and comprehensive loss | — | — | — | — | — | (19,884) | (439) | (20,323) |
| Balances at July 31, 2024 | 280,510 | $280,510 | 19,909,281 | $19,909 | $173,278 | $(426,319) | $16,661 | $(216,471) |
| Common Shares · AdditionalPaid-In · Accumulated · TotalShareholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity (Deficit) | |
| Balances at April 30, 2025 | 51,348,656 | $51,349 | $674,306 | $(520,249) | $205,406 |
| Share-based compensation expense | — | — | 4,579 | — | 4,579 |
| Net loss and comprehensive loss | — | — | — | (25,826) | (25,826) |
| Balances at July 31, 2025 | 51,348,656 | $51,349 | $678,885 | $(546,075) | $184,159 |
2 The number and amount of shares of common shares of Intermediate Holdings at a par value of $0.01 prior to the IPO has been retrospectively recast based on the number of Common Shares at a par value of $1.00 of Kestra Medical Technologies, Ltd. into which they were exchanged in connection with the Organizational Transactions prior to the IPO. Refer to Note 1 “The Company” for additional disclosure.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.